AR080027A1 - Proteinas de union a cd127 - Google Patents
Proteinas de union a cd127Info
- Publication number
- AR080027A1 AR080027A1 ARP110100251A ARP110100251A AR080027A1 AR 080027 A1 AR080027 A1 AR 080027A1 AR P110100251 A ARP110100251 A AR P110100251A AR P110100251 A ARP110100251 A AR P110100251A AR 080027 A1 AR080027 A1 AR 080027A1
- Authority
- AR
- Argentina
- Prior art keywords
- antigen binding
- diseases
- receptor
- nucleic acid
- human
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Se proporcionan proteínas de union a antígeno que se unen al receptor de IL-7 humano (CD127) y específicamente a la cadena alfa. Las proteínas de union a antígeno típicamente son anticuerpo, y son utiles en el tratamiento de enfermedades o trastornos en seres humanos, particularmente enfermedades autoinmunes tales como la esclerosis multiple. Además un anticuerpo humanizado comprendiendo al menos uno de un resto de lisina en la posicion 66, un resto de leucina en la posicion 69 o una valina en la posicion 71 de la region variable de la cadena pesada. Se proporciona además una molécula de ácido nucleico que codifica la proteína de union a antígeno que se une al receptor de IL-7 humano (CD127), un vector de expresion que comprende el ácido nucleico, una célula huésped recombinante que contiene al vector, una composicion farmacéutica y su uso en el tratamiento de enfermedades autoinmunes o inflamatorias.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29901010P | 2010-01-28 | 2010-01-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR080027A1 true AR080027A1 (es) | 2012-03-07 |
Family
ID=44320081
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110100251A AR080027A1 (es) | 2010-01-28 | 2011-01-26 | Proteinas de union a cd127 |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US9150653B2 (es) |
| EP (1) | EP2528947A4 (es) |
| JP (1) | JP5850860B2 (es) |
| KR (1) | KR20130028055A (es) |
| CN (1) | CN102812046B (es) |
| AR (1) | AR080027A1 (es) |
| AU (1) | AU2011209713B2 (es) |
| BR (1) | BR112012018914A2 (es) |
| CA (1) | CA2787070A1 (es) |
| CL (1) | CL2012002081A1 (es) |
| CO (1) | CO6592067A2 (es) |
| CR (1) | CR20120404A (es) |
| EA (1) | EA023700B1 (es) |
| IL (1) | IL220899A (es) |
| MA (1) | MA34004B1 (es) |
| MX (1) | MX339083B (es) |
| MY (1) | MY160590A (es) |
| NZ (1) | NZ601271A (es) |
| PE (2) | PE20170687A1 (es) |
| PH (1) | PH12012501549A1 (es) |
| SG (1) | SG182590A1 (es) |
| TW (1) | TWI489996B (es) |
| UA (1) | UA104663C2 (es) |
| UY (1) | UY33202A (es) |
| WO (1) | WO2011094259A2 (es) |
| ZA (1) | ZA201205624B (es) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE053720T2 (hu) | 2011-01-14 | 2021-07-28 | Univ California | ROR-1 fehérje elleni terápiás antitestek és eljárások alkalmazásukra |
| EP2583980A1 (en) * | 2011-10-19 | 2013-04-24 | Effimune | Antibodies directed against the alpha chain of IL7 receptor - their use for the preparation of drug candidates |
| EP2955196A1 (en) | 2014-06-10 | 2015-12-16 | Effimune | Antibodies directed against CD127 |
| MX2017004975A (es) | 2014-10-18 | 2017-06-30 | Pfizer | Composiciones de anticuerpos anti-il-7r. |
| AU2016239951A1 (en) | 2015-03-31 | 2017-09-07 | Sorriso Pharmaceuticals, Inc. | Polypeptides |
| AU2016239949A1 (en) | 2015-03-31 | 2017-09-07 | Sorriso Pharmaceuticals, Inc. | Peptide construct having a protease-cleavable linker |
| WO2017055966A1 (en) | 2015-10-01 | 2017-04-06 | Pfizer Inc. | Low viscosity antibody compositions |
| US11306140B2 (en) | 2016-01-07 | 2022-04-19 | The Schepens Eye Research Institute, Inc. | Therapeutics for ocular immunoinflammatory diseases |
| RS59223B1 (sr) | 2016-02-29 | 2019-10-31 | Ose Immunotherapeutics | Ne-antagonistička antitela usmerena protiv alfa lanca ekstracelularnog domena il7 receptora i njihova upotreba u lečenju kancera |
| MA45328A (fr) | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | Compositions acide nucléique-polypeptide et utilisations de celles-ci |
| MX2019006577A (es) * | 2016-12-09 | 2019-10-07 | Ose Immunotherapeutics | Anticuerpos y polipeptidos dirigidos contra cd127. |
| MA51583A (fr) * | 2018-01-04 | 2020-11-11 | Avidity Biosciences Inc | Molécules d'acide nucléique hétéroduplex et leurs utilisations |
| KR20230128134A (ko) * | 2019-01-22 | 2023-09-01 | 브리스톨-마이어스 스큅 컴퍼니 | Il-7r 알파 서브유닛에 대한 항체 및 이의 용도 |
| KR20220064953A (ko) | 2019-06-21 | 2022-05-19 | 소리소 파마슈티컬스 인크. | 폴리펩티드 |
| JP7692844B2 (ja) | 2019-06-21 | 2025-06-16 | ソリッソ ファーマシューティカルズ，インク． | ポリペプチド |
| MX2021015762A (es) | 2019-06-21 | 2022-04-18 | Sorriso Pharmaceuticals Inc | Composiciones. |
| CN110894237B (zh) * | 2019-12-05 | 2021-08-03 | 山东省分析测试中心 | 抗cd127的抗体、分泌该抗体的细胞株及其制备方法和应用 |
| GB2595299B (en) | 2020-05-21 | 2022-08-03 | Mabsolve Ltd | Modified immunoglobulin FC regions |
| US20220389104A1 (en) * | 2021-05-28 | 2022-12-08 | Ose Immunotherapeutics | Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 Agent |
| WO2023232826A1 (en) | 2022-05-30 | 2023-12-07 | Ose Immunotherapeutics | Biomarkers of il7r modulator activity |
| WO2024040195A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| EP4646274A1 (en) | 2023-01-06 | 2025-11-12 | Twain Therapeutics Pte. Ltd. | Antigen-binding molecules |
| EP4646437A1 (en) | 2023-01-06 | 2025-11-12 | Twain Therapeutics Pte. Ltd. | Antigen-binding molecules |
| EP4455308A1 (en) | 2023-04-24 | 2024-10-30 | Les Laboratoires Servier | Il-7r gene signatures |
| US12311033B2 (en) | 2023-05-31 | 2025-05-27 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025076127A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| WO2025098341A1 (en) * | 2023-11-10 | 2025-05-15 | Inmagene Biopharmaceuticals (Hangzhou) Co., Ltd. | IL-7Ra TARGETING ANTIBODIES AND USES THEREOF |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025202213A1 (en) | 2024-03-26 | 2025-10-02 | Institut National de la Santé et de la Recherche Médicale | Lipid nanoparticle loaded with antitumoral agent and functionnalized to target immosuppressive cells |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS57106673A (en) | 1980-12-24 | 1982-07-02 | Chugai Pharmaceut Co Ltd | Dibenzo(b,f)(1,4)oxazepin derivative |
| DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
| DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
| EP0368684B2 (en) | 1988-11-11 | 2004-09-29 | Medical Research Council | Cloning immunoglobulin variable domain sequences. |
| US20040049014A1 (en) * | 1988-12-28 | 2004-03-11 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
| US6291158B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertoire |
| EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
| CA2033082A1 (en) * | 1989-06-15 | 1990-12-16 | Linda S. Park | Interleukin-7 receptors |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| US6800738B1 (en) * | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
| ATE181571T1 (de) | 1991-09-23 | 1999-07-15 | Medical Res Council | Methoden zur herstellung humanisierter antikörper |
| GB9122820D0 (en) | 1991-10-28 | 1991-12-11 | Wellcome Found | Stabilised antibodies |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
| WO1994004690A1 (en) | 1992-08-17 | 1994-03-03 | Genentech, Inc. | Bispecific immunoadhesins |
| DK0703925T3 (da) | 1993-06-03 | 1999-12-06 | Therapeutic Antibodies Inc | Fremstilling af antistoffragmenter |
| US5429746A (en) | 1994-02-22 | 1995-07-04 | Smith Kline Beecham Corporation | Antibody purification |
| US5795737A (en) | 1994-09-19 | 1998-08-18 | The General Hospital Corporation | High level expression of proteins |
| EP0800536B1 (en) * | 1994-12-23 | 2006-11-29 | Smithkline Beecham Corporation | Recombinant il-5 antagonists useful in treatment of il-5 mediated disorders |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| DE69737188T2 (de) | 1996-05-04 | 2007-10-11 | Astrazeneca Ab | Monoklonaler antikoerper gegen cea, konjugate die dieses antikoerper enthalten und deren therapeutische verwendung in einem adept-system |
| AU743616B2 (en) | 1997-02-07 | 2002-01-31 | Merck & Co., Inc. | Synthetic HIV gag genes |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| GB9806530D0 (en) | 1998-03-26 | 1998-05-27 | Glaxo Group Ltd | Inflammatory mediator |
| IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
| US7115396B2 (en) | 1998-12-10 | 2006-10-03 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| ATE350661T1 (de) * | 1999-04-13 | 2007-01-15 | Wilex Ag | Diagnostischer und therapeutischer einsatz von antikörpern gegen den urokinase-rezeptor |
| AU7950400A (en) | 1999-10-19 | 2001-04-30 | Kyowa Hakko Kogyo Co. Ltd. | Process for producing polypeptide |
| ATE448301T1 (de) | 2000-09-08 | 2009-11-15 | Univ Zuerich | Sammlung von proteinen mit sich wiederholenden sequenzen (repeat proteins), die repetitive sequenzmodule enthalten |
| US6881557B2 (en) | 2001-07-12 | 2005-04-19 | Arrowsmith Technologies Llp | Super humanized antibodies |
| MXPA04001072A (es) | 2001-08-03 | 2005-02-17 | Glycart Biotechnology Ag | Variantes de glicosilacion de anticuerpos que tienen citotoxicidad celulares dependiente de anticuerpos incrementada. |
| GB0216648D0 (en) | 2002-07-18 | 2002-08-28 | Lonza Biologics Plc | Method of expressing recombinant protein in CHO cells |
| ES2562177T3 (es) | 2002-09-27 | 2016-03-02 | Xencor Inc. | Variantes de Fc optimizadas y métodos para su generación |
| EP2368578A1 (en) | 2003-01-09 | 2011-09-28 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| US20050025763A1 (en) | 2003-05-08 | 2005-02-03 | Protein Design Laboratories, Inc. | Therapeutic use of anti-CS1 antibodies |
| CA2531238C (en) | 2003-07-04 | 2015-02-24 | Affibody Ab | Polypeptides having binding affinity for her2 |
| AU2003275958A1 (en) | 2003-08-25 | 2005-03-10 | Pieris Proteolab Ag | Muteins of tear lipocalin |
| MXPA06006406A (es) | 2003-12-05 | 2007-03-21 | Adnexus Therapeutics Inc | Inhibidores de receptores de factor de crecimiento endotelial vascular tipo 2. |
| CA2573745A1 (en) | 2004-07-21 | 2007-01-12 | Glycofi, Inc. | Immunoglobulins comprising predominantly a glcnac2man3glcnac2 glycoform |
| WO2006052660A2 (en) * | 2004-11-04 | 2006-05-18 | Childrens Hospital Los Angeles Research Institute | Il-7 receptor blockade to suppress immunity |
| BRPI0719409A2 (pt) | 2006-12-18 | 2014-02-11 | Genentch Inc | "regiões variáveis da cadeia pesada ("vh"), sequências da cadeia vh, ácido nucléico, vetor, célula, anticorpos, uso do anticorpo, método para produzir um anticorpo, anticorpo anti-notch3 e forma humanizada do anticorpo" |
| EP1958957A1 (en) | 2007-02-16 | 2008-08-20 | NascaCell Technologies AG | Polypeptide comprising a knottin protein moiety |
| AU2009206724A1 (en) * | 2008-01-22 | 2009-07-30 | Biogen Idec Ma Inc. | RON antibodies and uses thereof |
| TW201018482A (en) * | 2008-08-08 | 2010-05-16 | Glaxo Wellcome Mfg Pte Ltd | Novel treatment |
-
2011
- 2011-01-26 MA MA35147A patent/MA34004B1/fr unknown
- 2011-01-26 WO PCT/US2011/022507 patent/WO2011094259A2/en not_active Ceased
- 2011-01-26 MX MX2012008765A patent/MX339083B/es active IP Right Grant
- 2011-01-26 MY MYPI2012003394A patent/MY160590A/en unknown
- 2011-01-26 UY UY0001033202A patent/UY33202A/es not_active Application Discontinuation
- 2011-01-26 SG SG2012053138A patent/SG182590A1/en unknown
- 2011-01-26 BR BR112012018914A patent/BR112012018914A2/pt not_active IP Right Cessation
- 2011-01-26 KR KR1020127022553A patent/KR20130028055A/ko not_active Abandoned
- 2011-01-26 EA EA201290589A patent/EA023700B1/ru not_active IP Right Cessation
- 2011-01-26 JP JP2012551247A patent/JP5850860B2/ja not_active Expired - Fee Related
- 2011-01-26 UA UAA201209254A patent/UA104663C2/ru unknown
- 2011-01-26 CN CN201180015856.0A patent/CN102812046B/zh not_active Expired - Fee Related
- 2011-01-26 PH PH1/2012/501549A patent/PH12012501549A1/en unknown
- 2011-01-26 TW TW100102962A patent/TWI489996B/zh not_active IP Right Cessation
- 2011-01-26 US US13/574,847 patent/US9150653B2/en not_active Expired - Fee Related
- 2011-01-26 AR ARP110100251A patent/AR080027A1/es unknown
- 2011-01-26 NZ NZ601271A patent/NZ601271A/en not_active IP Right Cessation
- 2011-01-26 AU AU2011209713A patent/AU2011209713B2/en not_active Ceased
- 2011-01-26 CA CA2787070A patent/CA2787070A1/en not_active Abandoned
- 2011-01-26 EP EP11737543.6A patent/EP2528947A4/en not_active Withdrawn
- 2011-01-26 PE PE2017000247A patent/PE20170687A1/es not_active Application Discontinuation
- 2011-01-26 PE PE2012001071A patent/PE20121702A1/es not_active Application Discontinuation
- 2011-01-26 US US13/013,993 patent/US8940303B2/en not_active Expired - Fee Related
-
2012
- 2012-07-12 IL IL220899A patent/IL220899A/en not_active IP Right Cessation
- 2012-07-24 CO CO12124175A patent/CO6592067A2/es active IP Right Grant
- 2012-07-25 ZA ZA2012/05624A patent/ZA201205624B/en unknown
- 2012-07-26 CL CL2012002081A patent/CL2012002081A1/es unknown
- 2012-07-31 CR CR20120404A patent/CR20120404A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR080027A1 (es) | Proteinas de union a cd127 | |
| EA201270571A1 (ru) | Человеческие il-23-антигенсвязывающие белки | |
| AR099288A1 (es) | Proteínas de fusión de interleucina-10 | |
| EA202091710A1 (ru) | Антитела против cd73 и способы их применения | |
| AR080229A1 (es) | Proteinas de dominio de armazon de fibronectina que se unen a il -23 (interleucina 23) | |
| EA201690377A1 (ru) | Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения | |
| EA201691304A1 (ru) | АНТАГОНИСТЫ НЕОНАТАЛЬНЫХ Fc-РЕЦЕПТОРОВ (FcRn) И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| UA113712C2 (xx) | Антитіло до fap і способи його застосування | |
| CO6710903A2 (es) | Un anticuerpo que reconoce y se une específicamente con un fosfo-epítope en la proteína tau de mamífero o en uno de sus fragmentos y una composición comprendiendo el mismo | |
| PE20140232A1 (es) | Proteinas de enlace antigeno capaz de enlazar linfopoyetina estromal timica | |
| MX395275B (es) | Construcciones con un dominio sirp-alfa o sus variantes | |
| EA201490745A1 (ru) | Полипептиды антител, которые вызывают антагонизм cd40l | |
| EP2575856A4 (en) | INNOVATIVE DETECTION OF THERAPEUTIC, DIAGNOSTIC AND ANTIBODY COMPOSITIONS IN CONNECTION WITH PROTEIN FRAGMENTS OF GLUTAMINYL-TRNA SYNTHETASES | |
| EA201390094A1 (ru) | ИННОВАЦИОННОЕ ОТКРЫТИЕ ТЕРАПЕВТИЧЕСКИХ КОМПОЗИЦИЙ, ДИАГНОСТИЧЕСКИХ КОМПОЗИЦИЙ И КОМПОЗИЦИЙ АНТИТЕЛ, СВЯЗАННЫХ С БЕЛКОВЫМИ ФРАГМЕНТАМИ АСПАРТИЛ-тРНК-СИНТЕТАЗ | |
| UA97516C2 (ru) | Полностью человеческое моноклональное антитело против vap-1 | |
| JOP20190097A1 (ar) | الجلوبولينات المناعية واستخداماتها | |
| CO6680693A2 (es) | Anticuerpos humanos recombinantes, tanto humanizados como quiméricos, los cuales en lazan especificamente a ox40 humano | |
| TR201906652T4 (tr) | Kademeli multimerize immünoglobülin fc bileşimleri oluşturmak için doğal insan protein fragmanları içeren füzyon proteinleri. | |
| EA201991409A2 (ru) | Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения | |
| PE20170519A1 (es) | Anticuerpos antagonistas del interferon alfa y omega | |
| EA201491784A1 (ru) | Антитела против лигандов рецептора в1 брадикинина | |
| AU2011353197A8 (en) | A cross linking polypeptide comprising an hexameric single chain antibody binding MHC-MAGE complex that induces apoptosis | |
| EA201591796A1 (ru) | Антитела к cd52 | |
| WO2012126118A8 (en) | Polypeptides with affinity for heat shock proteins (hsps) and hsp associated complexes (hacs) and their use in diagnosis and therapy | |
| CL2009001284A1 (es) | Anticuerpos o fragmentos de union a antigeno del mismo que se unen a il-21r; composicion farmaceutica que lo comprende; acidos nucleicos codificantes; vectores de expresion y celulas huesped aisladas; kit de diagnostico que comprende a dichos anticuerpos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |